"Receptor, ErbB-3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell surface protein-tyrosine kinase receptor that is specific for NEUREGULINS. It has extensive homology to and can heterodimerize with the EGF RECEPTOR and the ERBB-2 RECEPTOR. Overexpression of the erbB-3 receptor is associated with TUMORIGENESIS.
| Descriptor ID |
D020893
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.009.500 D12.776.543.750.630.009.500 D12.776.543.750.750.400.074.500 D12.776.624.664.700.790 D23.101.140.721
|
| Concept/Terms |
Receptor, ErbB-3- Receptor, ErbB-3
- ErbB-3 Receptor
- Receptor, ErbB 3
- Proto-Oncogene Protein erbB-3
- Proto Oncogene Protein erbB 3
- erbB-3, Proto-Oncogene Protein
- erbB-3 Protein
- erbB 3 Protein
- HER-3 Proto-Oncogene Protein
- HER 3 Proto Oncogene Protein
- Proto-Oncogene Protein, HER-3
- Tyrosine Kinase-type Cell Surface Receptor HER3
- Tyrosine Kinase type Cell Surface Receptor HER3
- Proto-Oncogene Proteins erbB-3
- Proto Oncogene Proteins erbB 3
- erbB-3, Proto-Oncogene Proteins
- Proto-oncogene-like Protein c-ErbB-2
- Protein c-ErbB-2, Proto-oncogene-like
- Proto oncogene like Protein c ErbB 2
- c-ErbB-2, Proto-oncogene-like Protein
- c-erbB-3 Protein
- c erbB 3 Protein
- Proto-Oncogene Protein c-erbB-3
- Proto Oncogene Protein c erbB 3
- c-erbB-3, Proto-Oncogene Protein
|
Below are MeSH descriptors whose meaning is more general than "Receptor, ErbB-3".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- ErbB Receptors [D08.811.913.696.620.682.725.400.009]
- Receptor, ErbB-3 [D08.811.913.696.620.682.725.400.009.500]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
- ErbB Receptors [D12.776.543.750.630.009]
- Receptor, ErbB-3 [D12.776.543.750.630.009.500]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- ErbB Receptors [D12.776.543.750.750.400.074]
- Receptor, ErbB-3 [D12.776.543.750.750.400.074.500]
- Neoplasm Proteins [D12.776.624]
- Oncogene Proteins [D12.776.624.664]
- Proto-Oncogene Proteins [D12.776.624.664.700]
- Receptor, ErbB-3 [D12.776.624.664.700.790]
- Biological Factors [D23]
- Biomarkers [D23.101]
- Biomarkers, Tumor [D23.101.140]
- Receptor, ErbB-3 [D23.101.140.721]
Below are MeSH descriptors whose meaning is more specific than "Receptor, ErbB-3".
This graph shows the total number of publications written about "Receptor, ErbB-3" by people in this website by year, and whether "Receptor, ErbB-3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 2 | 3 |
| 2017 | 0 | 2 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, ErbB-3" by people in Profiles.
-
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2024 Sep 20; 42(27):3228-3237.
-
Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies. Cancer Chemother Pharmacol. 2022 03; 89(3):347-361.
-
Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. Nat Commun. 2021 04 22; 12(1):2383.
-
A novel tumor inhibitory hybridoma monoclonal antibody with dual specificity for HER3 and HER2. Curr Res Transl Med. 2021 05; 69(2):103277.
-
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer. 2017 Sep 12; 17(1):646.
-
Integrated genomic and molecular characterization of cervical cancer. Nature. 2017 03 16; 543(7645):378-384.
-
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Mol Cancer Ther. 2016 09; 15(9):2175-86.
-
Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors. Mol Cancer Ther. 2016 07; 15(7):1746-56.
-
Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. J Clin Oncol. 2016 06 20; 34(18):2165-71.
-
Targeted Germline Modifications in Rats Using CRISPR/Cas9 and Spermatogonial Stem Cells. Cell Rep. 2015 Mar 24; 10(11):1828-35.